Mark Mirochnick

Summary

Affiliation: Boston University
Country: USA

Publications

  1. pmc Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus
    M Mirochnick
    Department of Pediatrics, Boston Medical Center, and Boston University School of Medicine, Massachusetts 02118, USA
    Antimicrob Agents Chemother 42:808-12. 1998
  2. ncbi request reprint Nevirapine concentrations in newborns receiving an extended prophylactic regimen
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 47:334-7. 2008
  3. doi request reprint Lopinavir exposure with an increased dose during pregnancy
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, and Infectious Disease Division, Children s Hospital Boston, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 49:485-91. 2008
  4. ncbi request reprint Pharmacokinetics of antiretrovirals in pregnant women
    Mark Mirochnick
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Clin Pharmacokinet 43:1071-87. 2004
  5. pmc Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy
    Mark Mirochnick
    Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Antimicrob Agents Chemother 53:1170-6. 2009
  6. doi request reprint Antiretroviral pharmacology: special issues regarding pregnant women and neonates
    Mark Mirochnick
    Division of Neonatology, Department of Pediatrics, Boston University School of Medicine, 771 Albany Street Dowling 4111, Boston, MA 02118, USA
    Clin Perinatol 37:907-27, xi. 2010
  7. ncbi request reprint Pharmacokinetics of oral zidovudine administered during labour: a preliminary study
    M Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118, and Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN, USA
    HIV Med 8:451-6. 2007
  8. ncbi request reprint Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection
    M Mirochnick
    Boston University School of Medicine, Boston, MA, USA
    Clin Pharmacol Ther 70:24-32. 2001
  9. pmc Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    Pediatr Infect Dis J 30:769-72. 2011
  10. ncbi request reprint Antiretroviral pharmacology in pregnant women and their newborns
    M Mirochnick
    Boston University School of Medicine, Boston Medical Center, One BMC Place, Boston, Massachusetts 02118, USA
    Ann N Y Acad Sci 918:287-97. 2000

Research Grants

Detail Information

Publications46

  1. pmc Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus
    M Mirochnick
    Department of Pediatrics, Boston Medical Center, and Boston University School of Medicine, Massachusetts 02118, USA
    Antimicrob Agents Chemother 42:808-12. 1998
    ..Potentially toxic concentrations may accumulate in serum if the standard dosage for full-term infants is used. We suggest that initial ZDV dosing should be reduced to 1.5 mg every 12 h for preterm neonates...
  2. ncbi request reprint Nevirapine concentrations in newborns receiving an extended prophylactic regimen
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 47:334-7. 2008
    ..The optimal neonatal antiretroviral (ARV) regimen for prevention of HIV mother-to-child transmission (MTCT) is unknown for infants born to mothers who receive no ARVs during pregnancy...
  3. doi request reprint Lopinavir exposure with an increased dose during pregnancy
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, and Infectious Disease Division, Children s Hospital Boston, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 49:485-91. 2008
    ..The goal of this study was to determine LPV exposure during the third trimester of pregnancy and 2 weeks postpartum with a higher LPV/RTV dose...
  4. ncbi request reprint Pharmacokinetics of antiretrovirals in pregnant women
    Mark Mirochnick
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Clin Pharmacokinet 43:1071-87. 2004
    ..Further investigations of antiretroviral pharmacology during pregnancy, including protein binding studies, are urgently needed...
  5. pmc Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy
    Mark Mirochnick
    Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Antimicrob Agents Chemother 53:1170-6. 2009
    ..The extent and effect of infant drug exposure via breast milk must be well understood in order to evaluate the benefits and risks of maternal antiretroviral use during lactation...
  6. doi request reprint Antiretroviral pharmacology: special issues regarding pregnant women and neonates
    Mark Mirochnick
    Division of Neonatology, Department of Pediatrics, Boston University School of Medicine, 771 Albany Street Dowling 4111, Boston, MA 02118, USA
    Clin Perinatol 37:907-27, xi. 2010
    ..This article reviews current knowledge of the pharmacology of these drugs during pregnancy and in the newborn period, highlighting those pharmacologic issues critical to the safe and effective use of antiretrovirals in these populations...
  7. ncbi request reprint Pharmacokinetics of oral zidovudine administered during labour: a preliminary study
    M Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118, and Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN, USA
    HIV Med 8:451-6. 2007
    ....
  8. ncbi request reprint Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection
    M Mirochnick
    Boston University School of Medicine, Boston, MA, USA
    Clin Pharmacol Ther 70:24-32. 2001
    ..Previous studies of dapsone pharmacokinetics in children have been too small to allow assessment of the relationships between dapsone pharmacokinetic parameters and patient characteristics or markers of efficacy and toxicity...
  9. pmc Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    Pediatr Infect Dis J 30:769-72. 2011
    ..There are no previous data describing nelfinavir and lamivudine pharmacokinetics in neonates treated with weight-band dosing regimens...
  10. ncbi request reprint Antiretroviral pharmacology in pregnant women and their newborns
    M Mirochnick
    Boston University School of Medicine, Boston Medical Center, One BMC Place, Boston, Massachusetts 02118, USA
    Ann N Y Acad Sci 918:287-97. 2000
    ..Adherence to antiretroviral regimens is a critical factor in determining the success of prophylactic and therapeutic regimens and is made difficult by the inability of infants to swallow pills and capsules...
  11. ncbi request reprint Nevirapine: pharmacokinetic considerations in children and pregnant women
    M Mirochnick
    Boston University School of Medicine, Massachusetts 02118, USA
    Clin Pharmacokinet 39:281-93. 2000
    ..Alternatively, children may receive 150 mg/m2 across all ages, once daily for the first 2 weeks of therapy followed by the same dose twice daily...
  12. ncbi request reprint Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets
    M Mirochnick
    Boston Medical Center Maternity 6, MA 02118, USA
    Am J Health Syst Pharm 57:1775-7. 2000
    ..Time to maximum serum concentration tended to be lower for the liquid, but not significantly. The liquid and tablet formulations of dapsone studied were found to be bioequivalent and may be used interchangeably...
  13. ncbi request reprint Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team
    M Mirochnick
    Department of Pediatrics, Boston Medical Center, Massachusetts 02118, USA
    J Infect Dis 178:368-74. 1998
    ..8 to 65.7 h. Administration of 200 mg orally to the mothers in labor and of a single 2-mg/kg oral dose to the infants at 48-72 h after birth maintained serum concentrations in the infants > 100 ng/mL through 7 days of life...
  14. pmc Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children
    M Mirochnick
    Boston Medical Center, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 43:2586-91. 1999
    ..Dapsone oral clearance appears to be increased in children under 2 years of age...
  15. ncbi request reprint Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose
    Mark Mirochnick
    Boston University School of Medicine, Boston Medical Center, 91 Concord Street, 6th Floor, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 33:153-6. 2003
    ..To evaluate cord blood and predose nevirapine concentrations in infants exposed to the two-dose intrapartum neonatal nevirapine regimen...
  16. ncbi request reprint Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment
    Roger L Shapiro
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, and Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Infect Dis 192:720-7. 2005
    ..The magnitude of infant antiretroviral (ARV) exposure from breast milk is unknown...
  17. pmc Atazanavir pharmacokinetics with and without tenofovir during pregnancy
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    J Acquir Immune Defic Syndr 56:412-9. 2011
    ..Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure...
  18. pmc Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
    ..2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported...
  19. ncbi request reprint Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial
    Alejandro Dorenbaum
    Department of Pediatrics, University of California, San Francisco, USA
    JAMA 288:189-98. 2002
    ..However, it is unknown whether the addition of the 2-dose nevirapine regimen to standard ART would further reduce perinatal HIV transmission...
  20. ncbi request reprint Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA
    J Acquir Immune Defic Syndr 39:189-94. 2005
    ..Further investigations of larger doses, such as 75 mg/kg twice a day, should be undertaken...
  21. pmc A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Infect Dis 54:285-93. 2012
    ..We hypothesized that increasing the duration or potency of the tail would further reduce this risk to <10%, using a sensitive assay to measure resistance...
  22. ncbi request reprint Concentrations of protease inhibitors in cord blood after in utero exposure
    Mark Mirochnick
    Boston University School of Medicine, and Statistical and Data Analysis Center Harvard School of Public Health, Boston, MA, USA
    Pediatr Infect Dis J 21:835-8. 2002
    ..To determine the concentrations of protease inhibitors in cord blood after prenatal protease inhibitor use by pregnant women...
  23. pmc Reduced indinavir exposure during pregnancy
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand Harvard School of Public Health, Boston, MA, USA Institut de Recherché pour le Développement IRD, UMI 174 PHPT, Marseille, France
    Br J Clin Pharmacol 76:475-83. 2013
    ..To describe the pharmacokinetics and safety of indinavir boosted with ritonavir (IDV/r) during the second and third trimesters of pregnancy and in the post-partum period...
  24. ncbi request reprint Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
    ..To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission...
  25. pmc Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants
    Patricia M Flynn
    St Jude Children s Research Hospital, Memphis, Tennessee 138105 2794, USA
    Antimicrob Agents Chemother 55:5914-22. 2011
    ..Rapidly decreasing TFV levels in infants suggest that multiple or higher doses of TDF will be necessary to maintain concentrations that are effective for viral suppression...
  26. ncbi request reprint Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group
    K McIntosh
    Children s Hospital, Division of Infectious Diseases, Boston, MA 02115, USA
    Pediatr Infect Dis J 18:432-9. 1999
    ..Design. Randomized, multicenter trial comparing daily (1 or 2 mg/kg) with weekly (4 mg/kg) dapsone regimens in 94 HIV-infected children intolerant to T/S...
  27. doi request reprint Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, Boston, MA Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD HIV AIDS Research Department, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Rio Grande do Sul, Brazil Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, CA Malawi College of Medicine, Blantyre, Malawi Infectious Diseases Department, Hospital Federal dos Servidores do Estado, Rio de Janiero, Brazil Department of Pediatrics, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Serviço de Infectologia, Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande do Sul, Brazil Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD Gilead Sciences, Foster City, CA Statistical Center for HIV AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD Family Health International, Durham, NC Makerere University Johns Hopkins University Research Collaboration, Kampala, Brazil
    J Acquir Immune Defic Syndr 65:33-41. 2014
    ..Data describing the pharmacokinetics and safety of tenofovir in neonates are lacking...
  28. ncbi request reprint Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus
    Alan M Fujii
    Department of Pediatrics, Boston University School of Medicine, Boston Medical Center, Boston, MA 02218, USA
    J Perinatol 22:535-40. 2002
    ..We conclude that in extremely premature infants, use of indomethacin during the first 48 hours of life was associated with a reduced need for PDA ligation, but an increased risk of NEC with intestinal perforation...
  29. pmc Effect of training traditional birth attendants on neonatal mortality (Lufwanyama Neonatal Survival Project): randomised controlled study
    Christopher J Gill
    Center for Global Health and Development, Boston University, Boston, MA, USA
    BMJ 342:d346. 2011
    ..To determine whether training traditional birth attendants to manage several common perinatal conditions could reduce neonatal mortality in the setting of a resource poor country with limited access to healthcare...
  30. ncbi request reprint Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team
    S A Nachman
    Department of Pediatrics, State University of New York at Stony Brook, 11794 8111, USA
    JAMA 283:492-8. 2000
    ..Although protease inhibitors are used routinely in adults with human immunodeficiency virus (HIV) infection, the role of these drugs in the treatment of clinically stable HIV-infected children is not clear...
  31. ncbi request reprint Evaluation of immune survival factors in pediatric HIV-1 infection
    W T Shearer
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Ann N Y Acad Sci 918:298-312. 2000
    ..Serum IgG level has been identified as an immune factor that independently predicts survival, in addition to the already established CD4+ T-cell count. The HIV-1 RNA and serum albumin levels also predicted survival...
  32. ncbi request reprint Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1
    H Jenson
    Department of Pediatrics, University of Texas Health Science Center, San Antonio, TX 78284 7811, USA
    J Infect Dis 179:1395-404. 1999
    ..Early EBV infection is common in children born to HIV-1-infected mothers. Children with rapidly progressive HIV-1 disease have more frequent EBV shedding...
  33. pmc Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children
    M E Feeney
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical Schoo, Boston, Massachusetts, USA
    J Virol 77:7492-501. 2003
    ..Moreover, this response has the potential to be broadened to target more epitopes, making these children attractive candidates for immunotherapeutic interventions...
  34. ncbi request reprint Evolution and transmission of stable CTL escape mutations in HIV infection
    P J Goulder
    Partners AIDS Research Center, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts 02114, USA
    Nature 412:334-8. 2001
    ..These data suggest that CTL escape mutations in epitopes associated with suppression of viraemia will accumulate as the epidemic progresses, and therefore have important implications for vaccine design...
  35. ncbi request reprint Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group
    S E Lipshultz
    Department of Cardiology, Children s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 97:1246-56. 1998
    ..The frequency of, course of, and factors associated with cardiovascular abnormalities in pediatric HIV are incompletely understood...
  36. pmc Antiretroviral regimens in pregnancy and breast-feeding in Botswana
    R L Shapiro
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 110 Francis St, Suite GB, Boston, MA 02215, USA
    N Engl J Med 362:2282-94. 2010
    ..The most effective highly active antiretroviral therapy (HAART) to prevent mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) in pregnancy and its efficacy during breast-feeding are unknown...
  37. doi request reprint Randomized controlled trial of feeding a concentrated formula to infants born to women infected by human immunodeficiency virus
    Harland S Winter
    Pediatric Gastroenterology and Nutrition Unit, MassGeneral Hospital for Children, Boston, MA 02114, USA
    J Pediatr Gastroenterol Nutr 49:222-32. 2009
    ..We tested the hypothesis that concentrated formula (CF) begun within the first 2 weeks of life increases growth in infants born to human immunodeficiency virus (HIV)-infected mothers...
  38. doi request reprint Assessment of adherence to antiretroviral therapy in perinatally HIV-infected children and youth using self-report measures and pill count
    John J Farley
    Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Dev Behav Pediatr 29:377-84. 2008
    ..The purpose of this study was to compare these different methods with one another and with viral load...
  39. ncbi request reprint Predictors of incident tuberculosis among HIV-1-infected women in Tanzania
    P A Venkatesh
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Tuberc Lung Dis 9:1105-11. 2005
    ..The development of tuberculosis (TB) in HIV-1-infected individuals is associated with accelerated HIV-1 disease progression...
  40. ncbi request reprint Pharmacokinetics and tolerance of zidovudine in preterm infants
    Edmund V Capparelli
    University of California, San Diego, USA
    J Pediatr 142:47-52. 2003
    ..To determine zidovudine pharmacokinetics and tolerance in premature human human immunodeficiency virus-exposed infants...
  41. ncbi request reprint Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
    J Brooks Jackson
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Lancet 362:859-68. 2003
    ..Safety and efficacy data are now presented for all babies followed up to 18 months of age...
  42. ncbi request reprint Pharmacotherapy of perinatal HIV
    Edmund Capparelli
    University of California, San Diego, Pediatric Pharmacology Research Unit, 4094 Fourth Street 201, San Diego, CA 92103, USA
    Semin Fetal Neonatal Med 10:161-75. 2005
    ..Although difficult to perform, clinical trials to determine the safety, pharmacokinetics and optimal dosing of antiretroviral in pregnant women and their newborns are urgently needed...
  43. pmc Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants
    Adriana H Tremoulet
    Division of Pharmacology and Drug Discovery, Pediatric Pharmacology Research Unit, University of California San Diego, MC 8214, San Diego, CA 92103 8214, USA
    Antimicrob Agents Chemother 51:4297-302. 2007
    ....
  44. ncbi request reprint Reduced lopinavir exposure during pregnancy
    Alice M Stek
    Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA
    AIDS 20:1931-9. 2006
    ..Pregnancy can alter antiretroviral pharmacokinetics. Our objective was to describe lopinavir/ritonavir (LPV/r) pharmacokinetics during pregnancy...
  45. ncbi request reprint Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission
    J Brooks Jackson
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    AIDS 20:217-22. 2006
    ..To correlate nevirapine presence and concentration in cord bloods of infants born to HIV-1 infected women with report of timing of dose and HIV-1 transmission at 6 weeks of age...
  46. ncbi request reprint Impact of pregnancy on abacavir pharmacokinetics
    Brookie M Best
    University of California San Diego, California 92103 8214, USA
    AIDS 20:553-60. 2006
    ..To describe abacavir pharmacokinetics during pregnancy and postpartum; physiological changes during pregnancy are known to affect antiretroviral drug disposition...

Research Grants2

  1. Antiretroviral Pharmacology/Lactating Mother/Infants
    Mark Mirochnick; Fiscal Year: 2006
    ..This information is needed for the safe and effective use of antiretrovirals in nursing women, and will pioneer a novel approach to the study of breast milk drug transfer. ..